Neuraxis secures key academic society guidelines recommendation for FAP

NeurAxis (NRXS) announced that its proprietary Percutaneous Electrical Nerve Field Stimulation, PENFS, technology has been officially incorporated into newly released clinical practice guidelines issued by the leading pediatric academic society for the treatment of Functional Abdominal Pain, FAP, in Irritable Bowel Syndrome. This inclusion represents a major catalyst for NeurAxis, unlocking the potential for large-scale insurance coverage for its flagship product, IB-Stim, and setting the stage for accelerated growth through evidence-based recommendations.